AstraZeneca Expects Exanta Experience To Benefit Future Anticoagulant R&D

AstraZeneca's experience with its failed anticoagulant Exanta (ximelagatran) will provide the company an advantage going forward in developing new oral anticoagulants, VP and Cardiovascular Therapy Area Head Gunnar Olsson maintained